Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: ≥98%
Description: CPI-360 is a novel, highly potent, selective, and SAM-competitive inhibitor of enhancer of zeste homolog 2 (EZH2) with potential antitumor activity. It inhibits wt EZH2 and Y641N EZH2 with an IC50 of 0.5 nM and 2.5 nM, respectively. CPI-360 exhibits excellent antiproliferative activity and high in vivo antitumor efficacy. It functions on the basis of S-adenosyl-Lmethionine (SAM)-competition, inhibits EZH1 about 100-fold less and shows exquisite selectivity across a large panel of histone lysine and arginine, and DNA methyltransferases. CPI-360 potently reduced global H3K27me3 and H3K27me2 levels in a dose dependent manner. CPI-360 effectively suppressed heavy H3K27me3 incorporation in KARPAS-422 cells without affecting total histone turnover.
ln Vitro |
|
||
---|---|---|---|
ln Vivo |
|
||
Animal Protocol |
|
||
References |
Chem Biol.2014 Nov 20;21(11):1463-75.
|
Molecular Formula |
C25H31N3O4
|
|
---|---|---|
Molecular Weight |
437.53
|
|
Exact Mass |
437.231
|
|
Elemental Analysis |
C, 68.63; H, 7.14; N, 9.60; O, 14.63
|
|
CAS # |
1802175-06-9
|
|
Related CAS # |
|
|
PubChem CID |
73442743
|
|
Appearance |
Solid powder
|
|
Density |
1.3±0.1 g/cm3
|
|
Boiling Point |
712.2±60.0 °C at 760 mmHg
|
|
Flash Point |
384.5±32.9 °C
|
|
Vapour Pressure |
0.0±2.3 mmHg at 25°C
|
|
Index of Refraction |
1.621
|
|
LogP |
2.2
|
|
Hydrogen Bond Donor Count |
2
|
|
Hydrogen Bond Acceptor Count |
4
|
|
Rotatable Bond Count |
6
|
|
Heavy Atom Count |
32
|
|
Complexity |
786
|
|
Defined Atom Stereocenter Count |
1
|
|
SMILES |
O1CCC(CC1)[C@@H](C)N1C2C=CC=CC=2C(C(NCC2C(NC(C)=CC=2OC)=O)=O)=C1C
|
|
InChi Key |
PFPSFENQCNMITC-MRXNPFEDSA-N
|
|
InChi Code |
InChI=1S/C25H31N3O4/c1-15-13-22(31-4)20(24(29)27-15)14-26-25(30)23-17(3)28(21-8-6-5-7-19(21)23)16(2)18-9-11-32-12-10-18/h5-8,13,16,18H,9-12,14H2,1-4H3,(H,26,30)(H,27,29)/t16-/m1/s1
|
|
Chemical Name |
N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-(oxan-4-yl)ethyl]indole-3-carboxamide
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.2856 mL | 11.4278 mL | 22.8556 mL | |
5 mM | 0.4571 mL | 2.2856 mL | 4.5711 mL | |
10 mM | 0.2286 mL | 1.1428 mL | 2.2856 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.